← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,515	+110	+8%	$18.4B
2	2 Charles River Laboratories CRL $14.4B	583	+27	+5%	$10.6B
3	3 CRISPR Therapeutics CRSP $4.86B	480	+39	+9%	$4.01B
4	4 BridgeBio Pharma BBIO $12.7B	435	+43	+11%	$14.4B
5	5 PTC Therapeutics PTCT $4.98B	353	+59	+20%	$7.04B
6	6 Sarepta Therapeutics SRPT $1.78B	347	+27	+8%	$2.01B
7	7 Krystal Biotech KRYS $9.79B	334	+50	+18%	$7.01B
8	8 Intellia Therapeutics NTLA $1.6B	293	+9	+3%	$938M
9	9 Ultragenyx Pharmaceutical RARE $1.47B	288	-15	-5%	$2.16B
10	10 Vericel Corp VCEL $2.06B	274	+25	+10%	$1.93B
11	11 uniQure QURE $1.45B	226	+7	+3%	$1.48B
12	12 DELISTED Arcellx ACLX	218	+9	+4%	$4.34B
13	13 Sana Biotechnology SANA $698M	203	+25	+14%	$649M
14	14 Legend Biotech LEGN $3.7B	200	0	0%	$1.91B
15	15 Taysha Gene Therapies TSHA $1.14B	195	+40	+26%	$1.48B
16	16 DELISTED BioLife Solutions BLFS	187	-5	-3%	$1.18B
17	17 Rocket Pharmaceuticals RCKT $243M	186	+13	+8%	$323M
18	18 Prime Medicine PRME $568M	183	+16	+10%	$336M
19	19 Precigen PGEN $2.63B	179	+12	+7%	$569M
20	20 Regenxbio RGNX $454M	174	+8	+5%	$593M
21	21 Allogene Therapeutics ALLO $449M	172	+2	+1%	$223M
22	22 4D Molecular Therapeutics FDMT $674M	153	+19	+14%	$402M
23	23 Fate Therapeutics FATE $232M	146	+3	+2%	$70.9M
24	24 Lexeo Therapeutics LXEO $216M	146	+37	+34%	$759M
25	25 Capricor Therapeutics CAPR $383M	132	+17	+15%	$791M